Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Gemphire Therapeutics Inc. (GEMP): Cormorant Asset Management Reports New Stake

Page 1 of 8

According to a new 13G filing with the Securities and Exchange Commission, Bihua Chen‘s Cormorant Asset Management owns 900,000 shares of Gemphire Therapeutics Inc. (NASDAQ:GEMP), which amass 9.7% of the company’s outstanding stock. Gemphire Therapeutics represents a new addition to Cormorant Asset Management’s portfolio.

Gemphire Therapeutics is a clinical-stage biopharmaceutical company engaged in discovering and producing therapeutics to help treat people suffering from dyslipidemia. The company started trading on August 8 and since then its stock has gained 8.7%.

Abbvie ABBV biopharmaceuticals cell blood dna gene stem test biotech research


There are no other funds in our database with a known long position in Gemphire Therapeutics Inc. (NASDAQ:GEMP) at this time.

Follow Gemphire Therapeutics Inc.
Trade (GEMP) Now!

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Cormorant Global Healthcare Master Fund 0 748,350 0 748,350 748,350 8.1%
Cormorant Global Healthcare GP 0 748,350 0 748,350 748,350 8.1%
Cormorant Asset Management 0 900,000 0 900,000 900,000 9.7%
Bihua Chen 0 900,000 0 900,000 900,000 9.7%

Bihua Chen
Bihua Chen
Cormorant Asset Management

Page 1 of 8 – SEC Filing

Washington, D.C. 20549
Under the Securities Exchange Act of 1934
(Amendment No. ___)*
Gemphire Therapeutics Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
(CUSIP Number)
August 5, 2016
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[ ]            Rule 13d-1(b)
[x]            Rule 13d-1(c)
[ ]            Rule 13d-1(d)
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 8